Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease

Study point of contact

Stephanie N Helwing, R.N.
(301) 827-0448
[email protected]

Locations

1 United States site

Age

18 to 99 Years

Genotypes

HbSS

Phase

Early Phase 1

Study type

Interventional

Gender

All

Interventions

Drug

Compensation

Unknown

About the study

Background:

Sickle cell disease (SCD) is an inherited blood disorder. It results from a single genetic
change (mutation) in red blood cells (RBCs). RBCs are the cells that carry oxygen to the
body. In people with SCD, some RBCs are abnormal and die early. This leaves a shortage of
healthy RBCs. Researchers want to learn more about how long RBCs live in the human body.

Objective:

To study how long RBCs live in people with and without SCD.

Eligibility:

People age 18 and older who either have SCD, had SCD but were cured with a bone marrow
transplant, have the sickle cell trait (SCT), or are a healthy volunteer without SCD or SCT

Design:

Participants will be screened with a medical history and physical exam. They will give a
blood sample.

Participants will have a small amount of blood drawn from a vein. In the laboratory, the
blood will be mixed with a vitamin called biotin. Biotin sticks to the outside of RBCs
without changing their function, shape, or overall lifetime. This process is known as biotin
labeling of RBCs. The biotin labeled RBCs will be returned to the participant via vein
injection.

Participants will give frequent blood samples. Their RBCs will be studied to see how many
biotin labeled RBCs remain over time. This shows how long the RBCs live. Participants will
give blood samples until no biotin labeled RBCs can be detected.

During the study visits, participants will report any major changes to their health.

Participation lasts for up to 6 months.

participation requirements

– Age 18 or greater with a confirmed diagnosis of homozygous sickle cell anemia (HbSS),
sickle cell trait (HbAS), or ethnic-matched healthy volunteer (HbA).

– Normal renal function: creatinine <1.5 mg/dL, proteinuria <1+. - Negative direct antiglobulin test (DAT). - Ability to give informed consent to participate in the protocol.

participation restrictions

– Any active chronic illness other than sickle cell disease.

– Blood transfusion within the preceding 90 days

– Active viral, bacterial, fungal, or parasitic infection.

– Consumption of biotin supplements or raw eggs within 30 days.

– Blood loss within the previous 8 weeks >30mL including but not limited by blood
donation, trauma, gastrointestinal bleeding.

– Pregnancy

– Pre-existing, naturally occurring antibodies against biotin

Locations

  • Bethesda, Maryland, United States, National Institutes of Health Clinical Center, 20892 [Recruiting]

More info

View on ClinicalTrials.gov
Site is under construction